Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure

Laura P. James, Lynda Letzig, Pippa M. Simpson, Edmund Capparelli, Dean W. Roberts, Jack A. Hinson, Timothy J. Davern, William M. Lee

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Acetaminophen (APAP)-induced liver toxicity occurs with formation of APAP-protein adducts. These adducts are formed by hepatic metabolism of APAP to N-acetyl-p-benzoquinone imine, which covalently binds to hepatic proteins as 3-(cystein-S-yl)-APAP adducts. Adducts are released into blood during hepatocyte lysis. We previously showed that adducts could be quantified by high-performance liquid chromatography with electrochemical detection following proteolytic hydrolysis, and that the concentration of adducts in serum of overdose patients correlated with toxicity. The following study examined the pharmacokinetic profile and clinical associations of adducts in 53 adults with acute APAP overdose resulting in acute liver failure. A population pharmacokinetic analysis using nonlinear mixed effects (statistical regression type) models was conducted; individual empiric Bayesian estimates were determined for the elimination rate constant and elimination half-life. Correlations between clinical and laboratory data were examined relative to adduct concentrations using nonparametric statistical approaches. Peak concentrations of APAP-protein adducts correlated with peak aminotransferase concentrations (r = 0.779) in adults with APAP-related acute liver failure. Adducts did not correlate with bilirubin, creatinine, and APAP concentration at admission, international normalized ratio for prothrombin time, or reported APAP dose. After N-acetylcysteine therapy, adducts exhibited first-order disappearance. The mean elimination rate constant and elimination half-life were 0.42 ± 0.09 days-1 and 1.72 ± 0.34 days, respectively, and estimates from the population model were in strong agreement with these data. Adducts were detected in some patient samples 12 days postingestion. The persistence and specificity of APAP-protein adducts as correlates of toxicity support their use as specific biomarkers of APAP toxicity in patients with acute liver injury.

Original languageEnglish (US)
Pages (from-to)1779-1784
Number of pages6
JournalDrug Metabolism and Disposition
Volume37
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Acute Liver Failure
Acetaminophen
Pharmacokinetics
Proteins
Liver
Half-Life
Imines
International Normalized Ratio
Prothrombin Time
Acetylcysteine
Statistical Models
Transaminases
Bilirubin
Population
Hepatocytes
Creatinine
Hydrolysis
Biomarkers
High Pressure Liquid Chromatography
Regression Analysis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. / James, Laura P.; Letzig, Lynda; Simpson, Pippa M.; Capparelli, Edmund; Roberts, Dean W.; Hinson, Jack A.; Davern, Timothy J.; Lee, William M.

In: Drug Metabolism and Disposition, Vol. 37, No. 8, 08.2009, p. 1779-1784.

Research output: Contribution to journalArticle

James, LP, Letzig, L, Simpson, PM, Capparelli, E, Roberts, DW, Hinson, JA, Davern, TJ & Lee, WM 2009, 'Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure', Drug Metabolism and Disposition, vol. 37, no. 8, pp. 1779-1784. https://doi.org/10.1124/dmd.108.026195
James, Laura P. ; Letzig, Lynda ; Simpson, Pippa M. ; Capparelli, Edmund ; Roberts, Dean W. ; Hinson, Jack A. ; Davern, Timothy J. ; Lee, William M. / Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. In: Drug Metabolism and Disposition. 2009 ; Vol. 37, No. 8. pp. 1779-1784.
@article{eb51d6e9bf724cdea627dc5207c4fd46,
title = "Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure",
abstract = "Acetaminophen (APAP)-induced liver toxicity occurs with formation of APAP-protein adducts. These adducts are formed by hepatic metabolism of APAP to N-acetyl-p-benzoquinone imine, which covalently binds to hepatic proteins as 3-(cystein-S-yl)-APAP adducts. Adducts are released into blood during hepatocyte lysis. We previously showed that adducts could be quantified by high-performance liquid chromatography with electrochemical detection following proteolytic hydrolysis, and that the concentration of adducts in serum of overdose patients correlated with toxicity. The following study examined the pharmacokinetic profile and clinical associations of adducts in 53 adults with acute APAP overdose resulting in acute liver failure. A population pharmacokinetic analysis using nonlinear mixed effects (statistical regression type) models was conducted; individual empiric Bayesian estimates were determined for the elimination rate constant and elimination half-life. Correlations between clinical and laboratory data were examined relative to adduct concentrations using nonparametric statistical approaches. Peak concentrations of APAP-protein adducts correlated with peak aminotransferase concentrations (r = 0.779) in adults with APAP-related acute liver failure. Adducts did not correlate with bilirubin, creatinine, and APAP concentration at admission, international normalized ratio for prothrombin time, or reported APAP dose. After N-acetylcysteine therapy, adducts exhibited first-order disappearance. The mean elimination rate constant and elimination half-life were 0.42 ± 0.09 days-1 and 1.72 ± 0.34 days, respectively, and estimates from the population model were in strong agreement with these data. Adducts were detected in some patient samples 12 days postingestion. The persistence and specificity of APAP-protein adducts as correlates of toxicity support their use as specific biomarkers of APAP toxicity in patients with acute liver injury.",
author = "James, {Laura P.} and Lynda Letzig and Simpson, {Pippa M.} and Edmund Capparelli and Roberts, {Dean W.} and Hinson, {Jack A.} and Davern, {Timothy J.} and Lee, {William M.}",
year = "2009",
month = "8",
doi = "10.1124/dmd.108.026195",
language = "English (US)",
volume = "37",
pages = "1779--1784",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure

AU - James, Laura P.

AU - Letzig, Lynda

AU - Simpson, Pippa M.

AU - Capparelli, Edmund

AU - Roberts, Dean W.

AU - Hinson, Jack A.

AU - Davern, Timothy J.

AU - Lee, William M.

PY - 2009/8

Y1 - 2009/8

N2 - Acetaminophen (APAP)-induced liver toxicity occurs with formation of APAP-protein adducts. These adducts are formed by hepatic metabolism of APAP to N-acetyl-p-benzoquinone imine, which covalently binds to hepatic proteins as 3-(cystein-S-yl)-APAP adducts. Adducts are released into blood during hepatocyte lysis. We previously showed that adducts could be quantified by high-performance liquid chromatography with electrochemical detection following proteolytic hydrolysis, and that the concentration of adducts in serum of overdose patients correlated with toxicity. The following study examined the pharmacokinetic profile and clinical associations of adducts in 53 adults with acute APAP overdose resulting in acute liver failure. A population pharmacokinetic analysis using nonlinear mixed effects (statistical regression type) models was conducted; individual empiric Bayesian estimates were determined for the elimination rate constant and elimination half-life. Correlations between clinical and laboratory data were examined relative to adduct concentrations using nonparametric statistical approaches. Peak concentrations of APAP-protein adducts correlated with peak aminotransferase concentrations (r = 0.779) in adults with APAP-related acute liver failure. Adducts did not correlate with bilirubin, creatinine, and APAP concentration at admission, international normalized ratio for prothrombin time, or reported APAP dose. After N-acetylcysteine therapy, adducts exhibited first-order disappearance. The mean elimination rate constant and elimination half-life were 0.42 ± 0.09 days-1 and 1.72 ± 0.34 days, respectively, and estimates from the population model were in strong agreement with these data. Adducts were detected in some patient samples 12 days postingestion. The persistence and specificity of APAP-protein adducts as correlates of toxicity support their use as specific biomarkers of APAP toxicity in patients with acute liver injury.

AB - Acetaminophen (APAP)-induced liver toxicity occurs with formation of APAP-protein adducts. These adducts are formed by hepatic metabolism of APAP to N-acetyl-p-benzoquinone imine, which covalently binds to hepatic proteins as 3-(cystein-S-yl)-APAP adducts. Adducts are released into blood during hepatocyte lysis. We previously showed that adducts could be quantified by high-performance liquid chromatography with electrochemical detection following proteolytic hydrolysis, and that the concentration of adducts in serum of overdose patients correlated with toxicity. The following study examined the pharmacokinetic profile and clinical associations of adducts in 53 adults with acute APAP overdose resulting in acute liver failure. A population pharmacokinetic analysis using nonlinear mixed effects (statistical regression type) models was conducted; individual empiric Bayesian estimates were determined for the elimination rate constant and elimination half-life. Correlations between clinical and laboratory data were examined relative to adduct concentrations using nonparametric statistical approaches. Peak concentrations of APAP-protein adducts correlated with peak aminotransferase concentrations (r = 0.779) in adults with APAP-related acute liver failure. Adducts did not correlate with bilirubin, creatinine, and APAP concentration at admission, international normalized ratio for prothrombin time, or reported APAP dose. After N-acetylcysteine therapy, adducts exhibited first-order disappearance. The mean elimination rate constant and elimination half-life were 0.42 ± 0.09 days-1 and 1.72 ± 0.34 days, respectively, and estimates from the population model were in strong agreement with these data. Adducts were detected in some patient samples 12 days postingestion. The persistence and specificity of APAP-protein adducts as correlates of toxicity support their use as specific biomarkers of APAP toxicity in patients with acute liver injury.

UR - http://www.scopus.com/inward/record.url?scp=67650802351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650802351&partnerID=8YFLogxK

U2 - 10.1124/dmd.108.026195

DO - 10.1124/dmd.108.026195

M3 - Article

C2 - 19439490

AN - SCOPUS:67650802351

VL - 37

SP - 1779

EP - 1784

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 8

ER -